Latest Equity Incentives News

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.

Catapult Group International Ltd reported a 16.5% increase in revenue to $116.5 million for FY25, driven by strong subscription growth and improved operational efficiency. The company narrowed its net loss after tax to $8.8 million, signaling progress in its global sports technology strategy.

Hearts & Minds Investments Limited is reshaping its leadership by appointing seasoned executive Richard Howes as part-time Managing Director, following operational upgrades under outgoing CEO Brett Jollie.

Sarama Resources reported a $673,644 net loss in Q1 2025 while progressing exploration in Western Australia and initiating a $120 million arbitration over a disputed Burkina Faso permit withdrawal.

Sarama Resources Ltd reported a $673,644 net loss for Q1 2025, reflecting ongoing exploration costs and capital raises, while navigating arbitration funding with Burkina Faso authorities.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.

Macarthur Minerals Limited reported a substantial loss of A$25.6 million for the nine months ending December 31, 2024, driven largely by the sale of its Hematite Project. Despite this setback, the company outlines plans for future funding and operational adjustments to sustain its business.

FireFly Metals Ltd reported a reduced half-year loss of A$5.7 million for December 2024, bolstered by a significant increase in cash reserves and strategic asset acquisitions in Canada and Australia.

Bastion Minerals has appointed Allister Caird as CEO and Dr Julian Stephens as Chief of Exploration and Strategy, signaling a strategic push to advance its Canadian copper projects with seasoned leadership.

Summit Minerals appoints Dr. Matthew Cobb as CEO to accelerate development of its Equador Niobium and Rare Earth Elements Project in Brazil, while reshuffling leadership to bolster operational focus.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.